More than a year later than expected, Sino-American oncology specialist BeiGene has at last secured US approval for its novel checkpoint inhibitor, tislelizumab 15 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.